NxStage Medical, Inc.  

(Public, NASDAQ:NXTM)   Watch this stock  
Find more results for NXTM
+0.10 (0.53%)
Jan 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.68 - 19.17
52 week 10.69 - 19.17
Open 18.79
Vol / Avg. 0.00/386,142.00
Mkt cap 1.17B
P/E     -
Div/yield     -
EPS -0.40
Shares 61.99M
Beta 0.56
Inst. own 99%
Feb 26, 2015
Q4 2014 NxStage Medical Inc Earnings Release - 9:30AM EST - Add to calendar
Jan 15, 2015
NxStage Medical Inc at JPMorgan Healthcare Conference
Dec 15, 2014
NxStage Medical Inc at Ernst & Young Boston Life Sciences Summit
Dec 3, 2014
NxStage Medical Inc at Piper Jaffray Healthcare Conference
Nov 11, 2014
NxStage Medical Inc at Stephens Fall Investment Conference
Nov 6, 2014
Q3 2014 NxStage Medical Inc Earnings Release
Nov 6, 2014
Q3 2014 NxStage Medical Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9.08% -7.05%
Operating margin -8.33% -6.76%
EBITD margin - 2.68%
Return on average assets -8.81% -6.00%
Return on average equity -14.31% -9.47%
Employees 3,200 -
CDP Score - -


United States - Map
+1-978-6874700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company�s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

Officers and directors

Joseph E. Turk Jr. President
Age: 46
Bio & Compensation  - Reuters
Jeffrey H. Burbank Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Towse CPA Chief Financial Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Robert S. Brown CPA President of NxStage Kidney Care
Age: 55
Bio & Compensation  - Reuters
Winifred L. Swan J.D. Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Todd M. Snell Senior Vice President - Quality Assurance, Regulatory & Clinical Affairs
Age: 42
Bio & Compensation  - Reuters
Robert G. Funari Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Jean K. Mixer Director
Age: 47
Bio & Compensation  - Reuters
Jay W. Shreiner Director
Age: 63
Bio & Compensation  - Reuters
Daniel A. Giannini CPA Independent Director
Age: 64
Bio & Compensation  - Reuters